vimarsana.com

Latest Breaking News On - Hungarian national institute of pharmacy - Page 1 : vimarsana.com

CanSinoBIO Receives European GMP Certification for its COVID-19 Vaccine Convidecia™

Vaccine has been approved in China, Mexico, Pakistan, Hungary and Chile Provides timely clinical protection for adults aged 18 and above, including those over 60 TIANJIN, China, May 24, 2021 /PRNewswire/ CanSino Biologics Inc. ( CanSinoBIO ) (SHSE: 688185, HKEX: 06185) today announced that its Recombinant Novel Coronavirus Vaccine, (Adenovirus Type 5 Vector) ( Ad5-nCoV , trade name: Convidecia™), has been granted a Good Manufacturing Practice ( GMP ) certificate by the Hungarian National Institute of Pharmacy and Nutrition (OGYÉI). The certification was issued on May 21, 2021 after a thorough inspection of CanSinoBIO s production of Convidecia™. The GMP certificate recognizes that CanSinoBIO s manufacturing facilities and quality control system comply with the high production standards and guidelines required by the European Union ( EU ). The EU GMP certification is required to import COVID-19 vaccines into the European Union and is regarded as a recognition of leading ind

CanSinoBIO Gets GMP Certificate for Its Vaccine to Enter European Countries

CanSinoBIO Gets GMP Certificate for Its Vaccine to Enter European Countries Hungarian National Institute of Pharmacy and Nutrition (OGYEI) has granted a Good Manufacturing Practice (GMP) certificate to CanSino Biologics, a Chinese vaccine manufacturer founded in 2009, for its COVID-19 vaccine known as Convidecia. According to details, OGYEI issued the GMP certificate to CanSinoBIO on 21 May after a comprehensive inspection of CanSinoBIO’s manufacturing of Convidecia. ALSO READ The GMP certificate by an EU member shows that CanSinoBIO’s manufacturing facilities and quality control system are in line with high production standards and guidelines laid down by the EU. The EU’s GMP certificate is required to import COVID-19 vaccines into Europe which indicates that CanSinoBIO is ready to enter more markets in Europe and globally.

CanSinoBIO Announces Approval for its Single-Dose COVID-19 Vaccine Convidecia™ in Hungary

Share this article Share this article Continues to boost production capacity to meet increasing demand Safe, stable storage and transportation between 2°C and 8°C, accessible by under-developed regions 95.47% effective overall in preventing severe COVID-19 diseases 14 days after vaccination Vaccines provide timely mass protection for adults aged 18 and above, including those over 60 TIANJIN, China, March 22, 2021 /PRNewswire/  CanSinoBIO Biologics Inc. ( CanSinoBIO ) (HKEX: 06185) today announced that the Hungarian National Institute of Pharmacy and Nutrition (OGYÉI) granted emergency use authorization for its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) ( Ad5-nCoV , trade name: Convidecia™). The approval is based on the vaccine s interim results for Phase III clinical trial and marks the first approval of Convidecia™ in an European Union member state.

Chile grants EUA to CanSinoBIO s single-dose Covid-19 vaccine

Chile grants EUA to CanSinoBIO’s single-dose Covid-19 vaccine Most Read Most Recent Most Read Most Recent 9 April 2021 (Last Updated April 9th, 2021 11:39) The Instituto de Salud Pública de Chile (ISP) has granted Emergency Use Authorization (EUA) to China-based company CanSino Biologics’ (CanSinoBIO) novel recombinant adenovirus type 5 vector Covid-19 vaccine Convidecia (Ad5-nCoV). Convidecia is the first single-dose vaccine to receive emergency use approval in Chile. Credit: CanSinoBIO. Share Article The Instituto de Salud Pública de Chile (ISP) has granted Emergency Use Authorization (EUA) to China-based company CanSino Biologics’ (CanSinoBIO) novel recombinant adenovirus type 5 vector Covid-19 vaccine Convidecia (Ad5-nCoV).

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.